Exposure-response relationship of certolizumab pegol induction and maintenance therapy in patients with Crohn's disease
نویسندگان
چکیده
منابع مشابه
Exposure‐response relationship of certolizumab pegol induction and maintenance therapy in patients with Crohn's disease
BACKGROUND Therapeutic drug monitoring may optimize therapy for Crohn's disease (CD). AIM To use a population pharmacokinetic model that accounts for the time-varying nature of covariates to simulate certolizumab pegol (CZP) concentrations to evaluate the exposure-response relationship for CZP in Crohn's disease. METHODS Adults (N = 2157) with Crohn's disease were treated with CZP in nine c...
متن کاملSimultaneous Exposure–Response Modeling of ACR20, ACR50, and ACR70 Improvement Scores in Rheumatoid Arthritis Patients Treated With Certolizumab Pegol
The Markovian approach has been proposed to model American College of Rheumatology's (ACR) response (ACR20, ACR50, or ACR70) reported in rheumatoid arthritis clinical trials to account for the dependency of the scores over time. However, dichotomizing the composite ACR assessment discards much information. Here, we propose a new approach for modeling together the three thresholds: a continuous-...
متن کاملEfficacy and safety of certolizumab pegol induction therapy in an unselected Crohn's disease population: results of the FACTS survey.
BACKGROUND Switzerland was the first country to approve certolizumab pegol (Cimzia, CZP) for the treatment of patients with moderate to severe Crohn's disease (CD) in September 2007. This phase IV study aimed to evaluate the efficacy and safety of CZP in a Swiss multicenter cohort of practice-based patients. METHODS Baseline and Week 6 evaluation questionnaires were sent to all Swiss gastroen...
متن کاملCertolizumab pegol in the treatment of Crohn's disease.
INTRODUCTION The introduction of antibodies directed against tumour necrosis factor (anti-TNF) has dramatically changed the concept of treating patients with Crohn's disease (CD). Unfortunately, the long-term efficacy of anti-TNF agents may be hampered by immunogenicity. The availability of more anti-TNF agents in the therapeutic armamentarium would therefore be of great benefit in patients loo...
متن کاملAdalimumab induction and maintenance therapy achieve clinical remission and response in Chinese patients with Crohn's disease
BACKGROUND/AIMS This was a Phase 2 study (NCT02015793) to evaluate the pharmacokinetics, safety, and efficacy of adalimumab in Chinese patients with Crohn's disease (CD). METHODS Thirty, adult Chinese patients with CD (CD Activity Index [CDAI] 220-450; high-sensitivity [hs]-C-reactive protein [CRP] ≥3 mg/L) received double-blind adalimumab 160/80 mg or 80/40 mg at weeks 0/2, followed by 40 mg...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Alimentary Pharmacology & Therapeutics
سال: 2017
ISSN: 0269-2813
DOI: 10.1111/apt.14421